RT journal article
T1 IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy – a retrospective case series focusing on dosing and tolerability
A1 León Valenzuela, Ángel
A1 Sánchez Palacios, Juan
A1 del Pino Algarrada, Rogelio
A2 Materno-Infantil y Radiología
K1 Spasticity
K1 Cerebral palsy
K1 Pediatric rehabilitation
AB Background: IncobotulinumtoxinA (Xeomin®) is a botulinum neurotoxin type A with established efficacy in the treatment of upper-limb spasticity in adults. This retrospective case series in a university hospital setting aimed to elucidate the safety and tolerability of incobotulinumtoxinA for treatment of spasticity in children with cerebral palsy.Methods: Participants received incobotulinumtoxinA injections up to a maximum total dose of 600 U, 24 U/kg body weight. Medical records were reviewed for key demographic information, incobotulinumtoxinA exposure, and adverse effects (AEs).Results: Sixty-nine children were included (mean age [SD], 8.3 [3.9] years; 44/69 [63.8%] male). One-hundred-and- ninety-one injections were administered, with mean (SD) of 2.8 (1.5) treatment cycles/participant and dosing interval of 6.0 (1.7) months. The number of muscles injected increased from 2.4 (1.2) at cycle 1 to 4.2 (1.9) at cycle 6. The mean (SD) total incobotulinumtoxinA dose increased from 191.7 (126.2) U, (8.5 [5.4] U/kg body weight) at cycle 1 to 368.0 (170.1) U, (9.9 [5.5] U/kg body weight) at cycle 6. Seventy four adverse effects (37.5% of injections) were reported, the most frequent was injection pain (93.2% of AEs). Only three AEs were considered directly treatment- related by injectors: muscle weakness, generalized weakness, and fever.Conclusions: Our clinical experience indicates that incobotulinumtoxinA is a well-tolerated treatment option for focal spasticity in children with cerebral palsy.
SN 1471-2377
YR 2020
FD 2020-04-08
LK http://hdl.handle.net/10498/26138
UL http://hdl.handle.net/10498/26138
LA eng
NO This article received funding support by Merz Pharmaceuticals GmbH,Frankfurt, Germany for technical manuscript translation and writingassistance by CMC Connect, a division of McCann Health MedicalCommunications Ltd., Glasgow, UK, under the supervision of the authors.Merz Pharmaceuticals did not participate in any of the other phases of thestudy (design, data collection, analysis and interpretation of results).
DS Repositorio Institucional de la Universidad de Cádiz
RD 11-nov-2026